RU2019140356A - Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений - Google Patents
Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений Download PDFInfo
- Publication number
- RU2019140356A RU2019140356A RU2019140356A RU2019140356A RU2019140356A RU 2019140356 A RU2019140356 A RU 2019140356A RU 2019140356 A RU2019140356 A RU 2019140356A RU 2019140356 A RU2019140356 A RU 2019140356A RU 2019140356 A RU2019140356 A RU 2019140356A
- Authority
- RU
- Russia
- Prior art keywords
- masp
- composition
- inhibiting
- disease
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
Claims (10)
1. Композиция для лечения индивидуума, страдающего или имеющего риск развития заболевания или нарушения, выбранного из группы, состоящей из болезни плотного депозита, слабоиммунного некротизирующего гломерулонефрита с полулуниями, травматического повреждения головного мозга, аспирационной пневмонии, эндофтальмита, нейромиелита зрительного нерва и болезни Бехчета, содержащая количество средства, ингибирующего MASP-2, эффективное для ингибирования MASP-2-зависимой активации комплемента, и фармацевтический носитель.
2. Композиция по п.1, где средство, ингибирующее MASP-2, представляет собой антитело против MASP-2 или его фрагмент.
3. Композиция по п.2, где средством, ингибирующим MASP-2, является моноклональное антитело против MASP-2 или его фрагмент, специфически связывающиеся с частью SEQ ID NO: 5.
4. Композиция по п.2, где антитело против MASP-2 представляет собой химерное, гуманизированное или человеческое антитело.
5. Композиция по любому из п.п.1-4, где композиция дополнительно содержит терапевтически эффективное количество средства, ингибирующего MASP-3.
6. Применение композиции, содержащей терапевтически эффективное количество средства, ингибирующего MASP-2, и фармацевтический носитель, в производстве лекарственного средства для ингибирования эффектов MASP-2-зависимой активации комплемента у индивидуума, страдающего или имеющего риск развития заболевания или нарушения, выбранного из группы, состоящей из болезни плотного депозита, слабоиммунного некротизирующего гломерулонефрита с полулуниями, травматического повреждения головного мозга, аспирационной пневмонии, эндофтальмита, нейромиелита зрительного нерва и болезни Бехчета.
7. Применение по п.6, где средство, ингибирующее MASP-2, представляет собой антитело против MASP-2 или его фрагмент.
8. Применение по п.7, где средством, ингибирующим MASP-2, является моноклональное антитело против MASP-2 или его фрагмент, специфически связывающиеся с частью SEQ ID NO: 5.
9. Применение по п.7, где антитело против MASP-2 представляет собой химерное, гуманизированное или человеческое антитело.
10. Применение по любому из п.п.6-9, где композиция дополнительно содержит терапевтически эффективное количество средства, ингибирующего MASP-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661167P | 2012-06-18 | 2012-06-18 | |
| US61/661,167 | 2012-06-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101230A Division RU2709351C2 (ru) | 2012-06-18 | 2013-06-18 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019140356A true RU2019140356A (ru) | 2020-01-27 |
Family
ID=49769678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019140356A RU2019140356A (ru) | 2012-06-18 | 2013-06-18 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
| RU2015101230A RU2709351C2 (ru) | 2012-06-18 | 2013-06-18 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101230A RU2709351C2 (ru) | 2012-06-18 | 2013-06-18 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20130344073A1 (ru) |
| EP (4) | EP4119577A3 (ru) |
| JP (4) | JP6445972B2 (ru) |
| KR (4) | KR20220100997A (ru) |
| CN (3) | CN104717975A (ru) |
| AU (3) | AU2013277309B2 (ru) |
| BR (1) | BR112014031522A2 (ru) |
| CA (2) | CA2875567C (ru) |
| CL (2) | CL2014003455A1 (ru) |
| CY (1) | CY1124234T1 (ru) |
| DK (1) | DK2861246T3 (ru) |
| ES (1) | ES2864857T3 (ru) |
| HK (1) | HK1209623A1 (ru) |
| HR (1) | HRP20210559T1 (ru) |
| HU (1) | HUE053727T2 (ru) |
| IL (2) | IL236327B (ru) |
| IN (1) | IN2015KN00015A (ru) |
| LT (1) | LT2861246T (ru) |
| MX (3) | MX2014015715A (ru) |
| NZ (1) | NZ629473A (ru) |
| PL (1) | PL2861246T3 (ru) |
| PT (1) | PT2861246T (ru) |
| RS (1) | RS61755B1 (ru) |
| RU (2) | RU2019140356A (ru) |
| SI (1) | SI2861246T1 (ru) |
| WO (1) | WO2013192240A2 (ru) |
| ZA (1) | ZA201500094B (ru) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010034015A2 (en) | 2008-09-22 | 2010-03-25 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| EP2694108B1 (en) | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| EP2968546B1 (en) | 2013-03-15 | 2023-09-20 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| WO2014169076A1 (en) * | 2013-04-09 | 2014-10-16 | Annexon,,Inc. | Methods of treatment for neuromyelitis optica |
| WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
| FI3019240T3 (fi) | 2013-07-09 | 2024-05-30 | Annexon Inc | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä |
| JP2016539919A (ja) | 2013-10-17 | 2016-12-22 | オメロス コーポレーション | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| CA2951159A1 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| BR112017009297B1 (pt) | 2014-11-05 | 2024-02-15 | Annexon, Inc | Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses |
| WO2016186994A1 (en) * | 2015-05-15 | 2016-11-24 | Children's Medical Center Corporation | Methods relating to the diagnosis and treatment of thrombotic microangiopathy |
| EP3302578A4 (en) * | 2015-06-03 | 2019-03-13 | Coyne Scientific, LLC | METHOD OF ESTABLISHING THRESHOLD LIMITS FOR A CHEMICAL OR BIOLOGICAL AGENT IN A TARGET SPECIES |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| GEP20247583B (en) | 2015-11-09 | 2024-01-10 | Univ Leicester | Methods for treating condi tions associated with masp-2 dependent complement activation |
| AU2016361517C1 (en) | 2015-11-24 | 2024-06-06 | Annexon, Inc. | Anti-complement factor C1q Fab fragments and uses thereof |
| IL294411A (en) * | 2016-01-05 | 2022-08-01 | Omeros Corp | masp-2 suppressors for use in suppressing fibrosis |
| CA3018774C (en) * | 2016-03-31 | 2023-02-28 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| JP7133561B2 (ja) | 2017-03-01 | 2022-09-08 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 医学的障害の治療のためのアリール、ヘテロアリール及び複素環式医薬化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3606965A4 (en) | 2017-04-03 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MASP-1 ANTIBODIES AND METHODS OF USE |
| MX2020002077A (es) * | 2017-08-25 | 2020-03-24 | Omeros Corp | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico. |
| AU2019250403A1 (en) * | 2018-04-13 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-complement component antibodies and methods of use |
| KR20210024003A (ko) * | 2018-06-22 | 2021-03-04 | 오메로스 코포레이션 | 다양한 혈전성 질환 및 장애의 치료를 위한 masp-2 억제 조성물 및 방법 |
| AU2019336238A1 (en) | 2018-09-06 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of Complement factor D inhibitors |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| JP2022502500A (ja) | 2018-09-25 | 2022-01-11 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ阻害剤の形態 |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| JP2022532069A (ja) | 2019-05-07 | 2022-07-13 | バイエル・アクチエンゲゼルシヤフト | Ｍａｓｐ阻害化合物およびその使用 |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CA3159172A1 (en) | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
| JP2023504544A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CN112237630A (zh) * | 2020-02-21 | 2021-01-19 | 中国人民解放军军事科学院军事医学研究院 | 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用 |
| TW202319069A (zh) * | 2020-03-06 | 2023-05-16 | 美商奥默羅斯公司 | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 |
| CN115215937B (zh) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| CN114989259B (zh) * | 2022-05-27 | 2023-06-09 | 成都佩德生物医药有限公司 | 一种小分子肽Ped4及应用 |
| WO2024118840A1 (en) | 2022-11-30 | 2024-06-06 | Omeros Corporation | Fused pyrimidines as masp-2 inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| EP1238066A2 (en) * | 1999-12-02 | 2002-09-11 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| DK1344533T3 (da) * | 2002-03-15 | 2007-01-08 | Natimmune As | Farmaceutiske præparater, der omfatter mannosebindende lectin |
| US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| CN101897969B (zh) * | 2003-02-21 | 2014-04-02 | 健泰科生物技术公司 | 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途 |
| WO2005005630A2 (en) * | 2003-07-08 | 2005-01-20 | Umc Utrecht Holding B.V. | Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| US20060002937A1 (en) * | 2004-06-10 | 2006-01-05 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN100518905C (zh) * | 2004-11-02 | 2009-07-29 | 浙江欧美环境工程有限公司 | 折返式电除盐器 |
| SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ595193A (en) * | 2005-10-21 | 2013-09-27 | Catalyst Biosciences Inc | Modified Proteases That Inhibit Complement Activation |
| ES2527695T3 (es) * | 2006-03-08 | 2015-01-28 | Archemix Llc | Aptámeros de unión a complemento y agentes anti-C5 útiles en el tratamiento de trastornos oculares |
| ES2628973T3 (es) | 2007-05-31 | 2017-08-04 | University Of Washington | Mutagénesis inducible de genes diana |
| PT2894165T (pt) * | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
| RU2012102021A (ru) * | 2009-06-23 | 2013-07-27 | Алексион Фармасьютикалз, Инк. | Биспецифические антитела, которые связываются с белками комплемента |
| EP3395828A1 (en) * | 2009-07-17 | 2018-10-31 | Rigshospitalet | Inhibitors of complement activation |
| CN106390117A (zh) * | 2009-10-16 | 2017-02-15 | 奥默罗斯公司 | 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法 |
| WO2011107591A1 (en) * | 2010-03-05 | 2011-09-09 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| US8795973B2 (en) * | 2010-11-29 | 2014-08-05 | University of Leceister | Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof |
| EP2694108B1 (en) * | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| RU2018114903A (ru) * | 2012-04-06 | 2019-03-04 | Омерос Корпорейшн | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
-
2013
- 2013-06-18 KR KR1020227022627A patent/KR20220100997A/ko not_active Application Discontinuation
- 2013-06-18 WO PCT/US2013/046432 patent/WO2013192240A2/en active Application Filing
- 2013-06-18 ES ES13807326T patent/ES2864857T3/es active Active
- 2013-06-18 PL PL13807326T patent/PL2861246T3/pl unknown
- 2013-06-18 CA CA2875567A patent/CA2875567C/en active Active
- 2013-06-18 CN CN201380044434.5A patent/CN104717975A/zh active Pending
- 2013-06-18 KR KR1020207003537A patent/KR20200015952A/ko not_active Application Discontinuation
- 2013-06-18 SI SI201331873T patent/SI2861246T1/sl unknown
- 2013-06-18 EP EP22177615.6A patent/EP4119577A3/en active Pending
- 2013-06-18 RU RU2019140356A patent/RU2019140356A/ru unknown
- 2013-06-18 CN CN201811331359.1A patent/CN109908352A/zh active Pending
- 2013-06-18 CN CN202210652007.6A patent/CN115040653A/zh active Pending
- 2013-06-18 EP EP21152111.7A patent/EP3878865A3/en not_active Withdrawn
- 2013-06-18 AU AU2013277309A patent/AU2013277309B2/en active Active
- 2013-06-18 RS RS20210465A patent/RS61755B1/sr unknown
- 2013-06-18 IN IN15KON2015 patent/IN2015KN00015A/en unknown
- 2013-06-18 KR KR1020207027432A patent/KR102339315B1/ko active IP Right Grant
- 2013-06-18 LT LTEP13807326.7T patent/LT2861246T/lt unknown
- 2013-06-18 HU HUE13807326A patent/HUE053727T2/hu unknown
- 2013-06-18 KR KR20157001304A patent/KR20150031298A/ko not_active IP Right Cessation
- 2013-06-18 JP JP2015518524A patent/JP6445972B2/ja active Active
- 2013-06-18 MX MX2014015715A patent/MX2014015715A/es unknown
- 2013-06-18 PT PT138073267T patent/PT2861246T/pt unknown
- 2013-06-18 BR BR112014031522A patent/BR112014031522A2/pt not_active Application Discontinuation
- 2013-06-18 NZ NZ629473A patent/NZ629473A/en unknown
- 2013-06-18 EP EP13807326.7A patent/EP2861246B1/en active Active
- 2013-06-18 RU RU2015101230A patent/RU2709351C2/ru active
- 2013-06-18 EP EP16150858.5A patent/EP3058951A1/en active Pending
- 2013-06-18 CA CA3214532A patent/CA3214532A1/en active Pending
- 2013-06-18 US US13/921,139 patent/US20130344073A1/en not_active Abandoned
- 2013-06-18 DK DK13807326.7T patent/DK2861246T3/da active
-
2014
- 2014-12-17 IL IL236327A patent/IL236327B/en active IP Right Grant
- 2014-12-17 MX MX2020005700A patent/MX2020005700A/es unknown
- 2014-12-17 MX MX2019012909A patent/MX2019012909A/es unknown
- 2014-12-18 CL CL2014003455A patent/CL2014003455A1/es unknown
-
2015
- 2015-01-07 ZA ZA2015/00094A patent/ZA201500094B/en unknown
- 2015-10-22 HK HK15110361.3A patent/HK1209623A1/xx unknown
-
2016
- 2016-12-22 CL CL2016003297A patent/CL2016003297A1/es unknown
-
2018
- 2018-06-15 AU AU2018204285A patent/AU2018204285B2/en active Active
- 2018-08-28 IL IL261436A patent/IL261436B/en unknown
- 2018-09-14 US US16/131,871 patent/US20190127484A1/en not_active Abandoned
- 2018-11-30 JP JP2018224961A patent/JP6771531B2/ja active Active
-
2020
- 2020-05-06 AU AU2020202999A patent/AU2020202999B2/en active Active
- 2020-09-29 JP JP2020163180A patent/JP2021006546A/ja active Pending
-
2021
- 2021-04-08 HR HRP20210559TT patent/HRP20210559T1/hr unknown
- 2021-04-20 CY CY20211100342T patent/CY1124234T1/el unknown
- 2021-10-11 US US17/498,559 patent/US20220259325A1/en not_active Abandoned
-
2022
- 2022-04-01 JP JP2022062008A patent/JP2022084946A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019140356A (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений | |
| JP2014534239A5 (ru) | ||
| JP2013542194A5 (ru) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| JP2018500014A5 (ru) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
| JP2015526440A5 (ru) | ||
| JP2014530226A5 (ru) | ||
| JP2014511179A5 (ru) | ||
| SI3042917T1 (en) | PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION | |
| JP2014530215A5 (ru) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| PH12017500493A1 (en) | Combination therapy | |
| JP2011157378A5 (ru) | ||
| JP2016503413A5 (ru) | ||
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| JP2016530223A5 (ru) | ||
| NZ629675A (en) | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria | |
| WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| JP2017529324A5 (ru) | ||
| RU2014117952A (ru) | Антитела против sema4a человека, используемые для лечения заболевания |